ABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC)

Documenti analoghi

• Nab-paclitaxel + durvalumab as second- or third-line treatment of advanced NSCLC: results from ABOUND.2l+
  di: Govindan, R, et al.
  Pubblicazione: (2017)
• Efficacy and safety of second- or third-line nab-paclitaxel + durvalumab in patients with advanced NSCLC (ABOUND.2L+)
  di: Morgensztern, D, et al.
  Pubblicazione: (2018)
• Quality of life in patients with advanced NSCLC treated in second- or third-line with nab-paclitaxel + durvalumab: abound.2l+
  di: Talbot, D, et al.
  Pubblicazione: (2018)
• nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+)
  di: Daniel Morgensztern, et al.
  Pubblicazione: (2021-02-01)
• ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin‐bound paclitaxel with or without CC‐486 as second‐line treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC)
  di: Morgensztern, D, et al.
  Pubblicazione: (2018)